Next-Generation Antibody Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Next-Generation Antibody Therapeutics market is segmented by Therapeutic Area (Oncology and Autoimmune or Inflammatory), Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Fc-Engineered Antibodies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD Million) for the above segments.

Next-Generation Antibody Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Next-Generation Antibody Therapeutics Industry Overview

The market for next-generation antibody therapeutics is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe, while others are launching new products. Some of the companies that are currently dominating the market are Amgen Inc., AstraZeneca Plc., Bayer AG, Biogen, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., ImmunoGen Inc., Kyowa Hakko Kirin Co., Ltd., Pfizer Inc., Seagen Inc., and Xencor, Inc., among others.

Next-Generation Antibody Therapeutics Market Leaders

  1. AstraZeneca Plc.

  2. Bristol-Myers Squibb Company

  3. F. Hoffmann-La Roche Ltd.

  4. Pfizer, Inc.

  5. Seagen Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Concentration.png